Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

The planned randomized Phase 3 trial will compare the daraxonrasib combination with standard-of-care chemotherapy.

Rhea-AI Summary

Tango Therapeutics (TNGX) reported an 82% objective response rate with vopimetostat plus daraxonrasib in previously treated pancreatic cancer patients.

At the August 20, 2026 cutoff, 22 evaluable patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma had median follow-up of 7.1 months. Median progression-free survival was not reached; the nine-month progression-free rate was 88%. Seven responses unconfirmed at cutoff were subsequently confirmed. At dose level 1, 40% of pancreatic cancer patients had Grade 3 treatment-related adverse events; dose level 2 was not well-tolerated.

The zoldonrasib combination produced a 54% response rate in 35 evaluable pancreatic cancer patients. Tango expects to start a front-line registrational Phase 3 daraxonrasib combination trial in 1H 2027 and intends to discuss a potential second-line approval pathway with regulators.

16 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointDaraxonrasib combination achieved 82% objective response rate (18/22) in evaluable second-/third-line pancreatic cancer patients.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Front-line registrational Phase 3 trial of vopimetostat plus daraxonrasib is expected to start in 1H 2027.
• Moderate pointZoldonrasib combination achieved 54% response rate (19/35), including 18 confirmed partial responses and one confirmed complete response.
• Minor pointDaraxonrasib combination delivered 88% nine-month progression-free survival; median progression-free survival was not yet reached.
• Minor pointDaraxonrasib combination achieved 100% disease control in evaluable pancreatic cancer patients.

11 minor points

• Minor pointDaraxonrasib combination responses included 11 confirmed and seven unconfirmed partial responses; all seven were confirmed after cutoff.
• Minor point. Forward-looking: it has not happened yet and may not happen.Second-line pancreatic cancer approval discussions with regulatory authorities are planned.
• Minor pointDaraxonrasib dose level 1 pancreatic cancer safety showed no dose-limiting toxicities or treatment-related withdrawals.
• Minor pointDaraxonrasib dose level 1 pancreatic cancer safety showed no Grade 4 or 5 treatment-related adverse events.
• Minor pointDaraxonrasib combination achieved 80% response rate (4/5 confirmed partial responses) in non-small cell lung cancer.
• Minor pointDaraxonrasib combination achieved 100% disease control in five non-small cell lung cancer patients.
• Minor pointDaraxonrasib dose level 1 lung cancer safety showed no Grade 4 or 5 treatment-related adverse events.
• Minor pointZoldonrasib combination delivered 61% nine-month progression-free survival in evaluable pancreatic cancer patients.
• Minor pointZoldonrasib combination achieved 97% disease control in evaluable pancreatic cancer patients.
• Minor pointZoldonrasib combination safety showed no dose-limiting toxicities or treatment-related withdrawals across dose levels.
• Minor pointZoldonrasib combination safety showed no Grade 5 treatment-related adverse events.

Negative

• Moderate pointDaraxonrasib dose level 2 was not well-tolerated, with three dose-limiting toxicities in two of four safety-evaluable patients.
• Minor pointDaraxonrasib dose level 1 pancreatic cancer patients had 40% Grade 3 treatment-related adverse events (10/25).
• Minor pointDaraxonrasib dose level 1 pancreatic cancer patients had a 20% dose-reduction rate (5/25).
• Minor pointDaraxonrasib pancreatic cancer side effects included stomatitis 48%, rash 44%, diarrhea 28%, all Grade 1–2.
• Minor pointDaraxonrasib dose level 1 lung cancer patients had 20% Grade 3 treatment-related adverse events (1/5).

5 minor points

• Minor pointDaraxonrasib lung cancer side effects: rash 100%, diarrhea 80%, stomatitis 40%, nausea 40%, fatigue 40%; all Grade 1–2.
• Minor pointZoldonrasib combination had one Grade 4 treatment-related adverse event (3%) among safety-evaluable patients.
• Minor pointZoldonrasib combination had 28% Grade 3 treatment-related adverse events (11/39).
• Minor pointZoldonrasib combination had a 15% dose-reduction rate (6/39).
• Minor pointZoldonrasib side effects included nausea 39%, vomiting 39%, dysgeusia 28%, fatigue 26%; all Grade 1–2.

News Explained

The planned front-line Phase 3 would compare the combination with standard chemotherapy in a 1:1 randomization, using response rate and progression-free survival as dual primary endpoints and overall survival as a key secondary endpoint.

Argus 15 min delay 14 alerts

+4.30% vs previous close $29.13 last price 120.6x rel. volume Open Argus

Details

Market move: TNGX +4.30% vs previous close. Phase 1/2 clinical data

+11.6% Peak Tracked

-16.7% Trough Tracked

$24.21 – $33.90 Day Range

$4.91B Mkt Cap at Last Price

On Oct 23, the day this news came out, the latest delayed price for TNGX is 4.30% above the previous close. Argus tracked a peak move of +11.6% during the session. Argus tracked a trough of -16.7% from its starting point during tracking. Our momentum scanner has recorded 14 alerts for this stock so far that day. The latest delayed price is $29.13. Relative volume is exceptionally heavy at 120.6x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Objective response rate: 82% 9-month PFS rate: 88% Median PFS: Not yet reached +4 more

Objective response rate

82%

22 efficacy-evaluable patients with 2L/3L MTAP-deleted/RAS-mutant PDAC; all dose levels

9-month PFS rate

88%

22 efficacy-evaluable patients with 2L/3L MTAP-deleted/RAS-mutant PDAC

Median PFS

Not yet reached

22 efficacy-evaluable patients with 2L/3L MTAP-deleted/RAS-mutant PDAC

Efficacy-evaluable patients

22 patients

2L/3L MTAP-deleted/RAS-mutant PDAC

Grade 3 TRAEs

40% (10/25)

Dose level 1 safety-evaluable patients

Planned Phase 3 study initiation

First half of 2027

Registrational study in front-line MTAP-deleted pancreatic cancer

Planned Phase 3 regimen

Vopimetostat 200 mg once daily plus daraxonrasib 100 mg once daily

One arm of the planned 1:1 randomized study

Previous Clinical trial Reports

1 past event · Latest: Oct 23

Same Type 1 event

1. Oct 23

   clinical data

   24h Move

   -13.1%

   Prior vopimetostat Phase 1/2 report showed 25% ORR in 2L MTAP-deleted pancreatic cancer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pfs, orr, pdac, dlts

4 terms

pfs medical

"median progression-free survival (PFS) not yet reached"

Progression-free survival (PFS) is a clinical-trial measure that records how long, on average, patients live without their disease getting worse after starting a treatment. For investors, PFS acts like a stopwatch of a drug’s effectiveness: longer PFS can signal meaningful patient benefit, improve chances of regulatory approval or label strength, and raise a drug’s commercial value, while shorter or unchanged PFS can weigh on a company’s prospects.

orr medical

"an 82% objective response rate (ORR)"

Objective Response Rate (ORR) is the percentage of patients in a clinical trial whose tumors shrink or disappear by a predefined amount after treatment. For investors, ORR is a quick, measurable signal of a therapy’s effectiveness—like early sales numbers for a new product—and strong ORR data can boost a drug’s commercial prospects and company valuation, while weak ORR can temper expectations.

pdac medical

"metastatic pancreatic ductal adenocarcinoma (PDAC)"

PDAC stands for pancreatic ductal adenocarcinoma, the most common and aggressive form of pancreatic cancer that starts in the pancreas’s duct cells. It matters to investors because PDAC represents a large unmet medical need with high patient mortality, driving intense drug development, clinical trial activity and potential regulatory milestones—like a critical, hard-to-fix engine part whose failure creates urgent demand for effective solutions, affecting a company’s valuation and risk profile.

dlts medical

"There were no dose-limiting toxicities (DLTs)"

Dose-limiting toxicities (DLTs) are the side effects in a clinical trial that are serious enough to prevent researchers from increasing a drug’s dose. They act like a safety stop sign, showing the highest tolerable dose and shaping the drug’s approved use, trial progress, development costs and timelines—factors that directly influence a biotech company’s regulatory prospects and investor value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib 

Vopimetostat combinations with RAS(ON) inhibitors daraxonrasib or zoldonrasib continued to be generally well-tolerated

Registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027

Investor webcast focused on PDAC to be held today at 7:30 a.m. ET

BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today announced promising results from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination with Revolution Medicines’ RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The results are being presented at the European Society for Medical Oncology (ESMO) 2026 Congress being held in Madrid, Spain on October 23-27, 2026.

As of the data cutoff date of August 20, 2026, updated data from the ongoing Phase 1/2 study demonstrated an 82% objective response rate (ORR), median PFS not yet reached, and a 9-month PFS rate of 88%, in 22 patients with 2L/3L MTAP-deleted/RAS-mutant PDAC who were efficacy-evaluable. The combination was generally well-tolerated in the 30 PDAC and NSCLC patients who received dose level 1.

“It is encouraging to see that the clinical activity and tolerability observed in our initial June 2026 dataset has been confirmed with longer follow-up and in a larger patient population, affirming our belief that the response rate and durability observed with vopimetostat plus daraxonrasib surpass any published PDAC datasets, even in front-line settings,” said Malte Peters, M.D., Chief Executive Officer and President of Tango Therapeutics. “Following discussions with the U.S. FDA, we are focused on initiating a planned registrational Phase 3 trial of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer in the first half of 2027. Given the data generated to date, we view PRMT5 inhibition as an emerging backbone in combination treatment strategies in PDAC and beyond. As a leader in the development of PRMT5-targeted therapies, we are also encouraged by the potential combinations of vopimetostat with RAS inhibitors in MTAP wild-type tumors, which we believe could further expand the impact of PRMT5 inhibition across a broader population of patients with PDAC.”

"For patients with pancreatic cancer, a highly aggressive malignancy that often progresses despite prior treatment, achieving durable disease control remains a significant challenge," said Alexander Spira, M.D., Co-Director of the Virginia Cancer Specialists Research Institute, NEXT Oncology, an Avacare business, and a principal investigator of the study. “In this updated analysis, the large majority of patients remained progression-free at nine months despite being heavily pretreated, with more than half receiving the combination as third-line therapy. Achieving this level of durability with an oral, chemotherapy-free regimen is particularly meaningful for patients and highlights the potential of a vopimetostat combination to redefine the standard of care in a disease that has been notoriously difficult to treat.”

“The depth and durability of responses reported with the vopimetostat and daraxonrasib combination are encouraging, particularly for patients who had already received multiple lines of treatment. We are excited by the potential of this biomarker-driven, targeted therapy approach and believe these results warrant rapid evaluation in a larger, randomized Phase 3 trial,” said Anna Berkenblit, M.D., MMSc, Chief Scientific & Medical Officer of the Pancreatic Cancer Action Network (PanCAN). “The approval of daraxonrasib marked the beginning of a new era for the pancreatic cancer community after a long wait, and we are looking forward to the next major advance that will translate into meaningful progress for patients quickly.”

Regulatory Update
Following recent interactions with the U.S. Food and Drug Administration (FDA), Tango plans to initiate a global, randomized registrational trial evaluating the combination of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted PDAC. The planned study will randomize patients 1:1 to receive either vopimetostat (200 mg once daily) plus daraxonrasib (100 mg once daily) or standard-of-care chemotherapy. The dual primary endpoints of the planned study are ORR and PFS, with overall survival as a key secondary endpoint. The Company anticipates initiating this study in the first half of 2027.

In addition, the Company intends to discuss the possibility of pursuing approval of this combination in patients with second-line PDAC with regulatory authorities.

Vopimetostat plus daraxonrasib data highlights
As of the data cutoff date of August 20, 2026, 34 patients with previously treated MTAP-deleted and RAS-mutant PDAC (n=29) or NSCLC (n=5) were treated with vopimetostat plus daraxonrasib. The majority of PDAC patients (13/22) who were efficacy-evaluable received the combination as third-line treatment. Efficacy-evaluable patients are those patients who received their first dose of treatment at least 14 weeks prior to the data cutoff date.

PDAC
In the vopimetostat plus daraxonrasib dose escalation arm, efficacy-evaluable patients received either vopimetostat 200 mg (n=19; dose level 1) or 250 mg (n=3; dose level 2) once daily (QD) plus daraxonrasib 100 mg QD. As of the data cutoff date of August 20, 2026, 22 patients were efficacy-evaluable, with median follow up of 7.1 months (range: 3.3-12.5 months).

Clinical activity, all dose levels:

• 82% ORR (18/22; 11 of 18 confirmed partial responses (cPRs), 7 unconfirmed partial responses; all unconfirmed responses confirmed after the data cutoff date)
• Median PFS not yet reached
• 88% 9-month PFS
• 100% disease control rate (DCR)

Safety and tolerability:

• Dose level 1 (n=25 safety-evaluable patients) was generally well-tolerated as of the data cutoff date:
  • There were no dose-limiting toxicities (DLTs)
  • There were no withdrawals due to treatment-related adverse events (TRAEs)
  • The rate of dose reduction was 20% (5/25)
  • There were no Grade 4 or 5 TRAEs
  • The rate of Grade 3 TRAEs was 40% (10/25)
  • The most common TRAEs were stomatitis (48%), rash (44%), and diarrhea (28%); all these events were Grade 1-2
• Dose level 2 (n=4 safety-evaluable patients) was not well-tolerated:
  • There were 3 DLTs in 2 patients
    

Safety-evaluable patients are those who received at least one dose of the applicable combination prior to the data cutoff date.

NSCLC

Clinical activity, dose level 1:

• 80% ORR (4/5 cPRs)
• 100% DCR

Safety and tolerability, dose level 1:

• There were no Grade 4 or 5 TRAEs
• The rate of Grade 3 TRAEs was 20% (1/5)
• The most common TRAEs were rash (100%), diarrhea (80%), stomatitis (40%), nausea (40%), and fatigue (40%); all these events were Grade 1-2.
  

Vopimetostat plus zoldonrasib combination (PDAC with MTAP deletion and KRAS G12D mutation)

In the vopimetostat plus zoldonrasib dose escalation arm, patients received vopimetostat 200 mg or 250 mg QD plus zoldonrasib 600 mg or 1200 mg QD across four dose levels (dose level 1: 200 mg/600 mg QD; dose level 2: 250 mg/600 mg QD; dose level 3: 250 mg/1200 mg QD; and dose level 4: 200 mg/1200 mg QD). As of the data cutoff date of August 20, 2026, 35 patients were efficacy-evaluable, meaning that they received their first dose of treatment at least 14 weeks prior to the data cutoff date. 39 patients were safety-evaluable, meaning they received at least one dose of this combination prior to the data cutoff date.

Data highlights include:

Clinical activity, all dose levels:

• 54% ORR (19/35; 18 cPRs,1 confirmed complete response)
• 61% 9-month PFS
• 97% DCR
  

Safety and tolerability, all dose levels:

Vopimetostat plus zoldonrasib was generally well-tolerated across dose levels:

• There were no DLTs
• There were no withdrawals due to TRAEs
• The rate of dose reduction was 15% (6/39)
• There were no Grade 5 TRAEs and there was one Grade 4 TRAE (3%)
• The rate of Grade 3 TRAEs was 28% (11/39)
• The most common TRAEs were nausea (39%), vomiting (39%), dysgeusia (28%) and fatigue (26%); all these events were Grade 1-2

PDAC-Focused Investor Webcast and Conference Call Information
The Company will host a PDAC-focused webcast to discuss these data at 7:30 a.m. ET today, October 23, 2026. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the Company website. Analysts who wish to join the teleconference and participate in Q&A should register here.

About Vopimetostat
Vopimetostat is an investigational, potentially first- and best-in-class oral, once-daily, PRMT5 inhibitor that is being evaluated as a monotherapy and as a combination therapy in multiple indications. In ongoing clinical studies, vopimetostat has demonstrated a favorable safety and tolerability profile and shown durable activity in multiple tumor types with MTAP (methylthioadenosine phosphorylase) deletion, including pancreatic cancer and lung cancer.

About Phase 1/2 Study of Vopimetostat Combinations with Daraxonrasib or Zoldonrasib
The ongoing Phase 1/2 open-label, dose-escalation and expansion trial is evaluating vopimetostat in combination with either daraxonrasib or zoldonrasib in patients with RAS-mutant, MTAP-deleted PDAC or NSCLC. The primary objective of the dose-escalation portion of the study was to determine the maximum tolerated dose of the combination regimens. Secondary objectives include assessment of antitumor activity, pharmacokinetics, safety and tolerability. Patients are treated until disease progression and may continue treatment beyond progression if, in the opinion of the investigator, they are deriving ongoing clinical benefit from therapy. To learn more about this study, visit clinicaltrials.gov (NCT06922591).

About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer. Using an approach that focuses on genetic vulnerabilities in cancer, Tango is pursuing PRMT5-targeted therapies designed to address pancreatic and other forms of cancer while sparing healthy normal tissues. For more information, please visit www.tangotx.com.

Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango Therapeutics and members of the Tango Therapeutics senior management team. Forward-looking statements are not purely historical and may be accompanied by words such as “may”, “should”, “expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”, “predict”, “designed,” “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: Dr. Peters’, Dr. Spira’s, and Dr. Berkenblit’s statements in this press release and statements regarding: (i) the potential of the Company’s PRMT5 molecules, as both standalone treatments and in combination with RAS(ON)-inhibitors, including the Company’s belief that vopimetostat (TNG462) has the potential to assist in treating patients with MTAP-deleted cancers; (ii) the preclinical research of the Company’s PRMT5 inhibitors, as a monotherapy and in combination, and the expectation that they may pave the way for future development opportunities, including expectations that vopimetostat (and its combination with RAS(ON) inhibitors) may be an important new therapy for MTAP-deleted cancers; (iii) expectations regarding the anticipated benefits of the Company’s molecules, development candidates, and product candidates; (iv) expectations for vopimetostat and the belief that vopimetostat has the potential to be a first- and best-in-class PRMT5 inhibitor for the treatment of MTAP-deleted cancers; (v) the Company’s development strategy in PRMT5-targeted therapies, including the ability of the Company’s vopimetostat clinical trials to inform a potential registrational trial in pancreatic cancer and the exploration of a vopimetostat RAS combination in MTAP wild-type tumors; (vi) the Company’s beliefs regarding the timing of upcoming clinical milestones and data disclosures, including, but not limited to: (a) the expected timing of clinical trial initiation, enrollment, dose escalation or dose expansion (including for combination studies) and (b) the expected timing of disclosing initial, interim, updated, additional, and final clinical trial results (including for combination studies); (vii) the Company’s plans, study design, doses, endpoints, and timing for combination trials, including the planned Phase 3 clinical trial evaluating vopimetostat with daraxonrasib in front-line patients with MTAP-deleted PDAC anticipated to be initiated in the first half of 2027; (viii) the Company’s expectations around regulatory communications and decisions related to its product candidates and clinical trials (including combination studies), including interactions with the FDA and other regulatory authorities; and (ix) the Company’s expectations regarding its ability to secure sufficient clinical supply of daraxonrasib for its planned Phase 3 clinical trial evaluating vopimetostat with daraxonrasib. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango Therapeutics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the benefits of product candidates, as single agents and/or in combination seen in preclinical tests and analyses and current and future clinical trials may not be evident or may differ materially when tested in later preclinical studies or in clinical trials or when used in broader patient populations (if approved for commercial sale); the Company’s effectiveness in managing current and future clinical trials, including maintaining anticipated timelines and reporting clinical trial results in the anticipated timeframe (or at all); the Company's reliance on third parties for conducting clinical trials and supplying and producing drug substance and drug product; expectations regarding the benefits and success of current or future collaborations and combination clinical trials; the Company's ability to enter into additional collaboration and supply agreements and to acquire, license, or otherwise obtain rights to additional products, product candidates, or molecules; the Company’s pipeline products may not be safe and/or effective in humans; the Company's ability to raise capital in the future and the potential delay, scale back or discontinuation of some of its development programs or future commercialization efforts if such funding is not available on acceptable terms (or at all); the Company’s product candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could, among other things, delay or prevent regulatory approval; government regulation, including inadequate funding for or disruptions at the FDA or other government agencies, may adversely affect the Company’s business. Additional information concerning risks, uncertainties and assumptions can be found in the Company’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as other filings the Company makes with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company specifically disclaims any duty to update these forward-looking statements.

Investors:
Elizabeth Hickin
ehickin@tangotx.com

Media:
1AB media
Amanda Lazaro
amanda@1abmedia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tango Therapeutics report for vopimetostat plus daraxonrasib in pancreatic cancer?

The combination produced an 82% objective response rate, meaning measurable tumor shrinkage, in 22 evaluable patients with previously treated MTAP-deleted, RAS-mutant pancreatic cancer. At the August 20, 2026 cutoff, median progression-free survival had not been reached, and the nine-month progression-free survival rate was 88%.

When does TNGX expect to start its pancreatic cancer Phase 3 trial?

Tango expects to initiate the front-line registrational trial of vopimetostat plus daraxonrasib in the first half of 2027. The planned trial will enroll patients with MTAP-deleted pancreatic ductal adenocarcinoma.

How will Tango Therapeutics structure the vopimetostat and daraxonrasib Phase 3 trial?

The planned global trial will randomly assign patients 1:1 to vopimetostat 200 mg once daily plus daraxonrasib 100 mg once daily or standard-of-care chemotherapy. Its dual primary endpoints are objective response rate and progression-free survival. Overall survival is a secondary endpoint.

Which patients counted as efficacy-evaluable in Tango Therapeutics' combination study?

Patients were efficacy-evaluable if they received their first treatment dose at least 14 weeks before the August 20, 2026 cutoff. Among the 22 evaluable pancreatic cancer patients receiving vopimetostat plus daraxonrasib, 13 received the combination as third-line treatment. Safety-evaluable patients had received at least one dose before cutoff.